Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
Drug Target Review
JUNE 6, 2023
This suppressive mechanism involves a negative regulator – a protein called IL-18BP or IL-18 binding protein, that works as a “decoy receptor” by binding to IL-18 and preventing it from binding to its functional receptor. Clinical development of IL-18 therapies has been curtailed, however, by the protein’s lack of efficacy.
98 
Let's personalize your content